The discussions of a potential merger between biotechnology companies NextCell Pharma AB and Idogen AB have been suspended due to deal structural disagreements. The two companies both develop cell therapy solutions, which also was the logic behind entering merger discussions.
ⓘ This story was originally featured in our daily Nordic M&A Newsletter - we publish some of the newsletter content with delay through our M&A Newsletter Library
. If you would like more insights on this deal or industry then send us an email at email@example.com